Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Common Equity: 2019-2024

Historic Common Equity for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $835.6 million.

  • Kymera Therapeutics' Common Equity rose 5.97% to $946.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.3 million, marking a year-over-year increase of 5.97%. This contributed to the annual value of $835.6 million for FY2024, which is 111.56% up from last year.
  • As of FY2024, Kymera Therapeutics' Common Equity stood at $835.6 million, which was up 111.56% from $395.0 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' Common Equity peaked at $835.6 million during FY2024, and registered a low of $283.9 million during FY2020.
  • Its 3-year average for Common Equity is $573.6 million, with a median of $490.2 million in 2022.
  • Per our database at Business Quant, Kymera Therapeutics' Common Equity skyrocketed by 481.54% in 2020 and then dropped by 19.42% in 2023.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Common Equity stood at $283.9 million in 2020, then spiked by 61.91% to $459.6 million in 2021, then increased by 6.64% to $490.2 million in 2022, then declined by 19.42% to $395.0 million in 2023, then skyrocketed by 111.56% to $835.6 million in 2024.